A network meta-analysis comparing anti-IL5 treatments in severe eosinophilic asthma using aggregate data

Trial description: Asthma is an inflammatory lung condition characterized by the narrowing of the airways, breathlessness, a tight chest and reduced quality of life. Mepolizumab, reslizumab and benralizumab are developed for the treatment of severe eosinophilic asthma. All three treatments have been shown to significantly reduce clinically significant exacerbations. However, subjects included within clinical trials conducted for these biologics differ in relation to blood eosinophils thresholds for inclusion in the trial. Hence, it is not clear which treatment might benefit subjects with similar characteristics. Blood eosinophils act as an effect modifier for all three treatments. A comparison of the relative efficacy of these three biologics can help for treatment decisions in subjects with severe eosinophilic asthma. The purpose of this analysis is to compare licensed doses of anti-IL5 treatments for subjects with severe eosinophilic asthma accounting for differences in subject’s characteristics between studies. This network meta-analysis will be conducted using available data from randomized controlled trials comparing mepolizumab, reslizumab, and benralizumab versus placebo. Data will be collected from peer-reviewed publications, regulatory (Food and Drug Administration [FDA], European Medicines Agency [EMA]) and reimbursement National Institute for Health and Clinical Excellence [NICE] documents, and ClinicalTrials.gov [CT.gov]).